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Abstract
Purpose Prostate cancer is the most commonly diagnosed
cancer in men. However, only about 12% of the men diag-
nosed with prostate cancer will die of their disease.
Result The serum PSA test can detect prostate cancers
early, but using a PSA based cut-oV indication for prostate
biopsy results in unnecessary testing in app. 75–80% of the
men and perhaps even more important the serum PSA test
cannot tell how aggressive the cancer is. To decrease
unnecessary testing diVerent test results are often com-
bined, converted into a probability and displayed graphi-
cally. There are more than 40 of these so called nomograms
in the case of prostate cancer. These nomograms can be
divided into two categories, namely those that predict
biopsy outcome using results from serum determination(s)
or non-invasive tests such as the DRE and TRUS. The sec-
ond category represents those nomograms that predict
tumor characteristics and prognosis using information com-
ing from pathology review.
Conclusion The ultimate nomogram able to predict tumor
characteristics and progression purely based on non-inva-
sive testing will for a large part put an end to the negative
side eVects and uncertainties that coincide with the early
detection of prostate cancer, if it will ever be made.
Keywords Prostate · Early detection · 
Indolent · Nomogram · PSA
Introduction
Prostate cancer is the most commonly diagnosed cancer in
men. However, only about 12% of the men diagnosed with
prostate cancer will die of their disease [1]. Already since
the early nineties there have been two mainstreams of
thinking about the early detection of prostate cancer using
the serum PSA test. One extreme is represented by those
who are deWnitely against screening for prostate cancer and
consider it as unwarranted [2, 3]; the opposite view is rep-
resented by those investigators who argue that men should
not be denied the opportunity of early detection and treat-
ment [4, 5].
In the past 15 years no consensus has emerged and pros-
tate cancer screening is still a controversial issue [6–12],
resulting in very diVerent screening policies in diVerent
countries, varying from very aggressive screening
algorithms, where men are screened every 6 to 12 months
starting as early as the age of 40, to no screening at all
[13–18].
Several studies have been undertaken to determine the
validity of mass screening [19–22]. The only scientiWcally
valid way to determine whether early detection indeed has
an eVect on prostate cancer mortality is a randomized con-
trolled trial with prostate cancer death as main endpoint.
Two large trials are ongoing namely the European Ran-
domised Study of Screening for Prostate Cancer (ERSPC)
[23] and the Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Trial [24] and an answer can be
expected within the next three years.
Population based screening for prostate cancer has not
been adopted in most health care systems due to this
uncertainty regarding its eYcacy in decreasing prostate
cancer speciWc mortality at an acceptable eVect on quality
of life and cost. In a population based setting, where many
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involved, speciWcity is a crucial issue.
So apart from the lack of evidence that early detection of
prostate cancer will indeed reduce prostate cancer mortality
the diVerences of opinion about prostate cancer screening
are mainly based on several issues relating to speciWcity.
The Wrst is the lack of a screening test or combination of
tests that can eYciently identify men with an elevated risk
of having prostate cancer in an asymptomatic population in
order to avoid unnecessary invasive testing. Next to this it
is not clear yet which men should actually be tested (age
cut-oV? high risk men? repeat biopsies?) and what should
be the optimal time period between subsequent screenings.
Finally there is the lack of knowledge about which prostate
cancers are life threatening, and need to be detected, and
which are not.
The concept of early detection and as a result oVering a
better chance of cure and reducing prostate cancer speciWc
mortality seems to speak for itself and sounds convincing.
But some prostate cancers develop so slowly that they
would likely never cause problems.
The serum PSA test can detect prostate cancers early,
but it cannot tell how aggressive the cancer is. Simply
because an elevated PSA level, some men will be diag-
nosed with a prostate cancer that would never have caused
any symptoms or lead to their death. They may however
still be treated with either surgery or radiation, either
because the uncertainty of the urologist on the aggressive-
ness of the cancer, or simply because the men are uncom-
fortable not having any treatment. These treatments can
have side eVects that seriously aVect a man’s quality of life.
The decision on who should receive treatment and who
might be able to be followed without being treated right
away (active surveillance) is one of the top priorities in
prostate cancer research at the moment [25–27] awaiting
the optimal approach for the early detection of prostate can-
cer; a non-invasive screening test which should be able to
predict the presence of a life threatening prostate cancer.
Screening tests
For a screening test to be useful, certain conditions must
be met: Wrstly the screening test must be valid. The valid-
ity is measured by its ability to distinguish between sub-
jects with the condition and those without. The validity of
a screening test is determined by its sensitivity and speci-
Wcity. These vary with the screening test, not the popula-
tion. A good screening test preferably will have a high
sensitivity and speciWcity and must be rapid, simple and
ideally non-invasive and acceptable for the population
screened. Sensitivity is deWned as the proportion of men
with a positive test result of those who truly have the
disease. SpeciWcity is deWned as the proportion of men
with a negative test result of those patients who are known
to be free of the disease. Also to be considered in the eval-
uation of a screening test is the positive predictive value
(PPV), which reXects the possibility that if the test is pos-
itive, the patient has the disease in question. To calculate
the true sensitivity the underlying prevalence of the dis-
ease should be known. This is not the case for prostate
cancer. Therefore, sensitivity is almost always based on
the number of positive biopsies in the screened population
as a “gold standard”. Sensitivity deWned in this way is
termed “relative sensitivity”. Next to the sensitivity of a
screening test the speciWcity is of great importance in a
population based screening program, simply because all
those with a positive screening test(s) need further
workup (i.e. prostate biopsy), which may cause unneces-
sary damage, mental stress and costs.
In prostate cancer screening there are basically three
tests that serve as indicators for the need of further testing,
i.e. the digital rectal examination (DRE), transrectal ultra-
sonography (TRUS and the derived prostate volume) and
most important, the serum prostate speciWc antigen (PSA)
level and its sub forms. Each individual screening test has
its plusses and minuses and often test results are combined
in order to get a more accurate prediction on the presence of
prostate cancer yes or no.
The combinations of test results that are converted into a
probability and displayed graphically are called nomo-
grams. In the case of prostate cancer more than 40 nomo-
grams have been published indicating the uncertainty in the
detection and management of prostate cancer that still exist
[28].
Nomograms can be seen as a physician with data of hun-
dreds or even thousands of patients stored inside his brain,
but without the human biases such as wishful thinking and
last case syndrome. The diVerent nomograms have been
developed for all steps during the path from the risk of hav-
ing a biopsy detectable prostate cancer to survival after the
development of metastatic disease.
Screening algorithms and nomograms for the detection 
of prostate cancer
The use of nomograms in the decision to perform a PSA
test or a prostate biopsy for the actual diagnosis of prostate
cancer is not standard practice. This is mainly caused by the
fact that most national guidelines do not recommend PSA
testing, however it is commonly known that opportunistic
PSA testing is common practice [29–33].
Several studies have been performed to assess the rea-
sons why physicians order a PSA test or why men want to
have a PSA test [34–37].123
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that any testing for cancer is so-called “responsible health
behavior”. Wives, friends and the media often trigger
requests for PSA testing. Next to this there is a lack of com-
munication about the uncertainty that is present in both the
test and treatment options. Discussions between physician
and patient on the pro’s and con’s of prostate cancer screen-
ing therefore sometimes do not occur.
A Wrst attempt to objectively help a man in the decision
to have a PSA test yes or no is made with the development
of the risk indicator® based on the screening results of men
participating in the Dutch part of the European Randomised
study of Screening for Prostate Cancer (ERSPC: http://
www.uroweb.org).
After the result of a PSA test is known the next question
is whether this test should be repeated and if so when or
whether a prostate biopsy is indicated or can be delayed or
is not necessary at all. Several studies have addressed this
issue and the general agreement is that rescreening intervals
should be related to the serum PSA level [38–40]. Inten-
sively screening in men with low PSA levels (i.e. <3.0 ng/
ml) will detect potentially life threatening cancers [41] but
at the same time has the great disadvantage of unnecessary
testing and overdiagnosis and subsequent overtreatment of
considerable more potentially indolent prostate cancers [42,
43]. Next to this it is shown that shortening of the screening
interval does not automatically lead to less (aggressive)
interval cases (prostate cancer diagnosed during the screen-
ing interval but not by screening) [44].
Up to now the decision to actually perform a prostate
biopsy is almost always based on a serum PSA level cut-oV
value, sometimes in combination with the results of the dig-
ital rectal examination (DRE) and/or derivates of the serum
PSA level (free PSA, free/total PSA ratio).
The most commonly used cut-oV values are 3.0 or
4.0 ng/ml which result in referral of app. 20–25% on
asymptomatic men in the age range 55–74 years.
There are however numerous studies that report on the
possible help of a nomogram.
These nomograms are predictive models that combine
available relevant pre-biopsy information into a probability
score, almost all claim a considerable decrease in the num-
ber of unnecessary biopsies depending on the probability
cut-oV used [45–49].
Readily available on line nomograms are the earlier
mentioned risk indicator® of ERSPC and the riskcalculator
of the prostate cancer prevention Trial (PCPT) (http://
www.compass.fhcrc.org/edrnnci/bin/calculator/).
The latest development in predicting biopsy outcome in
order to decrease the number of unnecessary biopsies is the
use of a urinary assay for PCA3. PCA3 turns out to be inde-
pendent of prostate volume, serum PSA level and the num-
ber of prior negative biopsies and could be incorporated
into a nomogram for improved prediction of biopsy out-
come [50].
Empiric data on the results of nomogram based screen-
ing for prostate cancer are not yet available. Although
results coming from the prostate arm of the Prostate Lung
Colorectal and Ovarian cancer screening trial (PLCO) and
its comparison with the purely PSA based screening results
of the Dutch part of ERSPC can give some insight in the
value of additional pre-biopsy information in the decision
to perform a biopsy [51, 52]. Within the PLCO algorithm
there is an additional step after PSA determination and
before taking a prostate biopsy. Participants with an ele-
vated PSA level or an abnormal DRE are advised to see
their primary care provider for diagnostic follow-up. He or
she used clinical judgment knowing other available infor-
mation such as previous PSA levels, prostate volume, fam-
ily history and previous negative biopsies in determining
who should get biopsied. This additional step resulted in a
38–40% higher PPV of the prostate biopsy depending on
the PSA level at the time of biopsy.
Algorithms and nomograms for the management 
of prostate cancer
After the diagnosis of prostate cancer is made the urologist
and patient are often confronted with yet another dilemma.
Radical prostatectomy, external beam radiotherapy, brach-
ytherapy or active surveillance are all potential treatment
options for patients with a clinically localized prostate can-
cer.
Choosing a therapy however does not only involve cure
or the avoidance/delay of metastases but co morbidity and
quality of life issues play an important role. Therefore indi-
vidual information on treatment success, complications and
related morbidity are essential in treatment decision making
for both urologist and patient. Since nomograms incorpo-
rate all relevant predictive factors available at individual
level they can provide very valuable information in the
decision process.
Although no surveys have been published that assess the
actual use of the nomograms available it is known from a
small survey done by ASCO in 2004 that the prostate can-
cer nomograms were the most common disease-speciWc
Palm applications among the Oncologists (personal com-
munication M Kattan).
Probably the best known prediction tool that helps with
treatment choice are the so-called Partin tables that using
clinical stage, biopsy Gleason score and pretreatment PSA
level to predict the pathological stage of the radical prosta-
tectomy specimen [53].
Several other nomograms have been developed that esti-
mate the likelihood of progression when choosing a certain123
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nomograms that predict the probability to remain free from
disease progression when choosing a radical prostatectomy
[54], external beam radiotherapy [55] and brachytherapy
[56].
Combining nomograms: the ultimate goal
After an initial period of optimism caused by the stage and
grade reduction at time of diagnosis as a result of the intro-
duction and application of the PSA test as a screening tool
doubts have arisen about PSA based screening. The ques-
tion arose whether all these low stage and low grade pros-
tate cancers should have been detected since they most
probably never would have surfaced clinically and thus
never would have caused any problems or would have
become life threatening. Nowadays low-risk or indolent
prostate cancer constitutes up to 50–60% of all newly diag-
nosed prostate cancers [1]. These insights triggered
researchers to develop nomograms that could predict the
chance on whether the cancer detected will lead to prostate
cancer death [57] or the likelihood of having an indolent
prostate cancer. Important to note is the fact that these pre-
diction tools require information coming from prostate tis-
sue thus can only be used after performing a prostate
biopsy.
An indolent prostate cancer that is deWned as a cancer
that does not need immediate invasive treatment but can be
monitored and treated curatively if progression should
occur. With doing so unnecessary invasive treatment can be
prevented in those men that will die of other causes than
their prostate cancer.
Kattan et al. [58] developed a nomogram to predict indo-
lent disease based on clinically detected prostate cancers,
which was later on adapted to a screening setting by Steyer-
berg et al. [59]. Basis for the calculations were prostate can-
cer cases with favorable characteristics such as a T1C or
T2A clinical stage, No Gleason pattern 4 or higher, 50% or
less positive cores and PSA at time of diagnosis less than
20 ng/ml.
Important diVerence between the two cohorts under
study was the percentage of men with high probabilities of
having an indolent prostate cancer within the strict inclu-
sion criteria. Within the screen detected cohort a third of
the men had predictions of 60% or higher while in the clin-
ical setting only a few cases had these high predictive prob-
abilities of having an indolent prostate cancer.
Together with the nomogram for prediction of indolent
prostate cancer in a screening setting suggestions for treat-
ment in combination with probability cut-oV values are
given. Conservative management may be appropriate in
patients with a high probability of indolent cancer, e.g.
exceeding 60%. In those with a low probability, e.g. less
than 30%, potentially curative management may possibly
be advised. This nomogram is also incorporated in the risk
indicator® and was applied to the prostate cancer cases
detected at initial and repeat screening within the ERSPC
section Rotterdam. It turned out that 17% of the prostate
cancer cases detected at initial screening and 45% of the
cases detected at repeat screening 4 years later had a proba-
bility of being indolent of more than 60%. This means that
within a PSA based screening setting a substantial percent-
age of the cancers detected can be identiWed as potentially
indolent and can therefore be considered for active surveil-
lance [60].
Being a relatively new treatment option for prostate can-
cer the guidelines for active surveillance are not quite clear
yet. Uncertainties currently exist concerning the risk of
missing the window of curability and criteria to rely of for
changing from active surveillance to curative therapy in
time [61].
One of the initiatives to gain more insight into these
uncertainties is the initiation by the department of Urology
of the Erasmus Medical Center in Rotterdam of the web
based prospective PRIAS trial (Prostate cancer Research
International: Active Surveillance, http://www.prias-pro-
ject.org) [62].
Other ongoing studies on the value of active surveillance
for potentially indolent prostate cancer are the prospective
cohort of Klotz [63] in Canada and at the Royal Marsden
Hospital in the UK [64].
However both the individualization of the screening
algorithm with the possible use of nomograms and the
application of active surveillance for those prostate cancers
that most probably are over diagnosed are in fact temporary
measurements that do not solve the actual problem in pros-
tate cancer screening namely not being able to identify life
threatening prostate cancer before invasive testing such as a
prostate biopsy is performed.
Passing this Wnal hurdle would require a combination of
the available nomograms on predicting biopsy outcome
(mostly based on laboratory measurements and non-inva-
sive tests) and the nomograms on predicting the presence of
a life threatening or indolent prostate cancer (up to now
only based on pathological data coming from prostate
biopsy or even radical prostatectomy specimens).
A Wrst attempt to assess the eVect of a nomogram based
biopsy indication instead of a PSA cut-oV based biopsy
indication in combination with the characteristics of can-
cers that would have been detected or missed was done
with applying the risk indicator® disk three and four to men
screened at initial and repeat screening within ERSPC Rot-
terdam [65].
Applying a nomogram that predicts biopsy outcome
based on results of PSA, DRE, TRUS, prostate volume123
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negative biopsy and choosing a probability cut-oV of 15%
or higher as trigger for prostate biopsy resulted 31% less
biopsies in men initially screened and 46% less biopsies in
men previously screened. The prostate cancer diagnoses
that would have been missed when applying this biopsy
indication consisted for res. 70% (initial screening) and
90% (repeat screening) of potentially indolent cases (calcu-
lated with disk four of the risk indicator®).
Conclusions
Whether or not the early detection of prostate cancer will
save lives remains unknown at this moment. Implementing
national population based screening programs will largely
depend on the outcome of these trials. However it is very
unlikely that screening for prostate cancer will be discon-
tinued at this point in time and guidelines on how to screen
for prostate cancer in a well-considered manner are an
important need.
A nomogram that predicts the characteristics and course
of the prostate cancer without invasive testing will very
likely put an end on the most debated topic within the uro-
logical world, if it will ever become available. Using a
nomogram should always be done with a critical mind since
predictions on the presence or characteristics of the prostate
cancer in an individual are based on study cohorts, with
each having their own speciWc characteristics.
Therefore it is of up most importance to realize whether
the nomogram that is used when counseling a patient is
externally validated and applicable to his situation [66–68].
The ongoing randomized screening trials, the discovery
of new biomarkers and the prospective treatment trials will
without doubt provide the information needed to develop
the ultimate nomogram for prostate cancer screening.
ConXict of interest statement There is no conXict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Can-
cer statistics,2007. CA Cancer J Clin 57(1):43–66
2. Adami HO, Baron JA, Rothman KJ (1994) Ethics of a prostate
cancer screening trial. Lancet 343(8903):958–960
3. Barry MJ (2006) The PSA Conundrum. Arch Intern Med
166(1):7–8
4. Catalona WJ (1993) Screening for prostate cancer: enthusiasm.
Urology 42(2):113–115
5. Walsh PC (1994) Prostate cancer kills: strategy to reduce deaths.
Urology 44(4):463–466
6. Oottamasathien S, Crawford ED (2003) Should routine screening
for prostate-speciWc antigen be recommended? Arch Intern Med
163(6):661–662
7. HoVman RM (2003) An argument against routine prostate cancer
screening. Arch Intern Med 163(6):663–665 discussion 665–6
8. Frankel S, Smith GD, Donovan J, Neal D (2003) Screening for
prostate cancer. Lancet 361(9363):1122–1128
9. Wilson SS, Crawford ED (2004) Screening for prostate cancer.
Clin Prostate Cancer 3(1):21–25
10. Brawley OW (2004) Prostate cancer screening: Clinical applica-
tions and challenges. Urol Oncol 22(4):353–357
11. HoVman RM (2006) Viewpoint: limiting prostate cancer screen-
ing. Ann Intern Med 144(6):438–440
12. Catalona WJ, Loeb S, Han M (2006) Viewpoint: expanding pros-
tate cancer screening. Ann Intern Med 144(6):441–443
13. Smith RA, Cokkinides V, Eyre HJ (2006.) American Cancer Soci-
ety guidelines for the early detection of cancer. CA Cancer J Clin.
56:11–25,2004 54(1):41–52
14. Prostate Cancer Early Detection. http://www/nccn.org/physi-
cian_gls/f_guidelines.html. editor: national Comprehensive Can-
cer Network, 2004
15. American Urological Association (2000) Prostate-speciWc antigen
(PSA) best practice policy. Oncology 14:277–278
16. NHG-standaard bemoeilijkte mictie bij oudere mannen. http://
nhg.artsennet.nl/upload/104/standaarden/M42/svk.htm. editor:
Nederlands huisartsen Genootschap
17. UK National Screening Committee’s Policy Positions. http://
www.nelh.nhs.uk/screening/policy positionchart2.pdf. editor: UK
national Screening Committee 2004
18. Albertsen PC (2005) What is the value of screening for prostate
cancer in the US? Nat Clin Pract Oncol 2(11):536–537
19. De Antoni EP (1997) Eight years of “Prostate Cancer Awareness
Week”: lessons in screening and early detection. Prostate Cancer
Education Council. Cancer 80(9):1845–1851
20. Crawford ED (1997) Prostate Cancer Awareness Week: Septem-
ber 22 to 28, 1997. CA Cancer J Clin 47(5):288–296
21. Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau
G, Chevrette E, Lévesque J (2004) Screening decreases prostate
cancer mortality: 11-year follow-up of the 1988 Quebec prospec-
tive randomized controlled trial. Prostate 59(3):311–318
22. Horniger W, Reissigl A, Rogatsch H, Volgger H, Studen M,
Klocker H, Bartsch G (2000) Prostate cancer screening in the Ty-
rol, Austria: experience and results. Eur J Cancer 36(10):1322–
1335
23. Roobol MJ, Schröder FH (guest editors). European Randomized
Study of Screening for Prostate Cancer: rationale, structure and
preliminary results 1994–2003. BJU Int. 2003 Dec;92 Suppl 2:1–
122
24. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Craw-
ford ED, Fogel R,Gelmann EP, Gilbert F, Hasson MA, Hayes RB,
Johnson CC, Mandel JS, Oberman A, O’Brien B, Oken MM, RaXa
S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Pros-
tate, Lung, Colorectal and Ovarian Cancer Screening Trial Project
Team. Design of the Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Trial. Control Clin Trials 2000
Dec;21(6 Suppl):273S–309S
25. Dall’era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen
PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace
ME, KantoV PW, Carroll PR. Active surveillance for early-stage
prostate cancer: review of the current literature. Cancer. 2008 Feb
27; [Epub ahead of print]
26. Klotz L (2008) Low-risk prostate cancer can and should often be
managed with active surveillance and selective delayed interven-123
428 World J Urol (2008) 26:423–429tion. Nat Clin Pract Urol.5(1):2–3. Epub 2007 Nov 27. No abstract
available
27. Dall’era MA, Konety BR (2008) Active surveillance for low-risk
prostate cancer: selection of patients and predictors of progression.
Nat Clin Pract Urol
28. Stephenson AJ, Kattan MW (2006) Nomograms for prostate can-
cer. BJU Int 98(1):39–46 Review
29. Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C,
Lous JJ, Cuzick J, Schröder FH (2007) Feasibility study of adjust-
ment for contamination and non-compliance in a prostate cancer
screening trial. Prostate 67(10):1053–1060
30. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ,
Schröder FH, de Koning HJ (2003) EVective PSA contamination
in the Rotterdam section of the European Randomized Study of
Screening for Prostate Cancer. Int J Cancer 105(3):394–399
31. Farwell WR, Linder JA, Jha AK (2007) Trends in prostate-speciWc
antigen testing from 1995 through 2004. Arch Intern Med
167(22):2497–2502
32. Jønler M, Eddy B, Poulsen J (2005) Prostate-speciWc antigen test-
ing in general practice: a survey among 325 general practitioners
in Denmark. Scand J Urol Nephrol 39(3):214–218
33. Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR
(2007) Practitioner-level determinants of inappropriate prostate-
speciWc antigen screening. Arch Intern Med 167(13):1367–1372
34. Chapple A, Ziebland S, Hewitson P, McPherson A (2008) Why
men in the United Kingdom still want the prostate speciWc antigen
test. Qual Health Res 18(1):56–64
35. Guerra CE, Jacobs SE, Holmes JH, Shea JA (2007) Are physicians
discussing prostate cancer screening with their patients and why or
why not? A pilot study. J Gen Intern Med 22(7):901–907
36. O’Dell KJ, Volk RJ, Cass AR, Spann SJ (1999) Screening for
prostate cancer with the prostate-speciWc antigen test: are patients
making informed decisions? J Fam Pract 48(9):682–688
37. Gattellari M, Ward JE (2005) Men’s reactions to disclosed and
undisclosed opportunistic PSA screening for prostate cancer. Med
J Aust 182(8):386–389
38. Roobol MJ, Roobol DW, Schröder FH (2005) Is additional testing
necessary in men with prostate-speciWc antigen levels of 1.0 ng/
mL or less in a population-based screening setting? (ERSPC, sec-
tion Rotterdam). Urology 65(2):343–346
39. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J
(2005) Individualized screening interval for prostate cancer based on
prostate-speciWc antigen level: results of a prospective, randomized,
population-based study. Arch Intern Med 165(16):1857–1861
40. Kobayashi T, Goto R, Ito K, Mitsumori K (2007) Prostate cancer
screening strategies with re-screening interval determined by indi-
vidual baseline prostate-speciWc antigen values are cost-eVective.
Eur J Surg Oncol 33(6):783–789
41. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ,
Crowley JJ, Parnes HL, Coltman CA Jr (2005) Operating charac-
teristics of prostate-speciWc antigen in men with an initial PSA lev-
el of 30 ng/ml or lower. JAMA 294(1):66–70
42. Schröder FH, Bangma CH, Roobol MJ (2008) Is It Necessary to
Detect All Prostate Cancers in Men with Serum PSA
Levels <3.0 ng/ml? A Comparison of Biopsy Results of PCPT and
Outcome-Related Information from ERSPC. Eur Urol. Jan 28;
[Epub ahead of print]
43. Welch HG, Schwartz LM, Woloshin S (2005) Prostate-speciWc
antigen levels in the United States: implications of various deWni-
tions for abnormal. J Natl Cancer Inst 97(15):1132–1137
44. Roobol MJ, Grenabo A, Schröder FH, Hugosson J (2007) Interval
cancers in prostate cancer screening: comparing 2- and 4- year
screening intervals in the European Randomized Study of Screen-
ing for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer
Inst 99(17):1296–1303
45. Eastham JA, May R, Robertson JL, Sartor O, Kattan MW (1999)
Development of a nomogram that predicts the probability of a pos-
itive prostate biopsy in men with an abnormal digital rectal exam-
ination and a prostate-speciWc antigen between 0 and 4 ng/mL.
Urology 54(4):709–713
46. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M,
Beer TM, Klein T (2003) Predictive modeling for the presence of
prostate carcinoma using clinical, laboratory, and ultrasound
parameters in patients with prostate speciWc antigen levels &lt;
or = 10 ng/mL. Cancer 98(7):1417–1422
47. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette
L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG,
Huland H, Graefen M (2005) Development and validation of a
nomogram predicting the outcome of prostate biopsy based on pa-
tient age, digital rectal examination and serum prostate speciWc
antigen. J Urol 173(6):1930–1934
48. Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni
V, Gallina A, Walz J, Haese A, Steuber T, Erbersdobler A, Sch-
lomm T, Ahyai SA, Currlin E, Valiquette L, Heinzer H, Rigatti P,
Huland H, Karakiewicz PI (2007) Development and external vali-
dation of an extended 10-core biopsy nomogram. Eur Urol
52(2):436–444
49. Roobol MJ, Schröder FH, Kranse R (2006) ERSPC, Rotterdam A
comparison of Wrst and repeat (four years later) prostate cancer
screening in a randomized cohort of a symptomatic men aged 55–
75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC,
Rotterdam). Prostate 66(6):604–612
50. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis
WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. (2008)
PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy
Outcome. J Urol. [Epub ahead of print]
51. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF,
Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian
G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK (2005) PLCO
Project Team. Prostate Cancer Screening in the Prostate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Trial: Wndings
from the initial screening round of a randomized trial. J Natl Can-
cer Inst 97(6):433–438
52. Roobol MJ (2006) The use of nomograms in the detection of pros-
tate cancer. Prostate 66(12):1266–1267
53. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC,
Epstein JI, Partin AW (2007) Updated nomogram to predict path-
ologic stage of prostate cancer given prostate-speciWc antigen lev-
el, clinical stage, and biopsy Gleason score (Partin tables) based on
cases from 2000 to 2005. Urology 69(6):1095–1101
54. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino
PT (1998) A preoperative nomogram for disease recurrence fol-
lowing radical prostatectomy for prostate cancer. J Natl Cancer
Inst 90(10):766–771
55. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Lei-
bel SA (2000) Pretreatment nomogram for predicting the outcome
of three-dimensional conformal radiotherapy in prostate cancer. J
Clin Oncol 18(19):3352–3359
56. Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh
W, Leibel S, Scardino PT (2001) Pretreatment nomogram for pre-
dicting freedom from recurrence after permanent prostate brachy-
therapy in prostate cancer. Urology 58(3):393–399
57. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes follow-
ing conservative management of clinically localized prostate can-
cer. JAMA 293(17):2095–2101
58. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT,
Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin
KM, Ohori M (2003) Counseling men with prostate cancer: a
nomogram for predicting the presence of small, moderately diVer-
entiated, conWned tumors. J Urol 170(5):1792–1797123
World J Urol (2008) 26:423–429 42959. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de
Koning HJ, Schröder FH (2007) Prediction of indolent prostate
cancer: validation and updating of a prognostic nomogram. J Urol
177(1):107–112 discussion 112.
60. Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyer-
berg EW, Schröder FH (2007) Nomogram use for the prediction of
indolent prostate cancer: impact on screen-detected populations.
Cancer 110(10):2218–2221
61. Bratt O (2006) Watching the face of Janus–active surveillance as
a strategy to reduce overtreatment for localised prostate cancer.
Eur Urol 50(3):410–412
62. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schröder
FH, Bangma CH (2007) Prospective validation of active surveil-
lance in prostate cancer: the PRIAS study. Eur Urol 52(6):1560–
1563
63. Klotz L (2007) Active surveillance for favorable risk prostate
cancer: rationale, risks, and results. Urol Oncol 25(6):505–509
Review
64. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R,
Dearnaley D (2005) Early outcomes of active surveillance for
localized prostate cancer. BJU Int 95(7):956–960
65. Roobol MJ, Wolters T, van den Bergh RCN, Schröder FH (2008)
PSA based screening for prostate cancer modiWed by probability
cut-oV levels (ERSPC Rotterdam). ASCO poster # A2, San Fran-
cisco.
66. Stephenson AJ, Kattan MW (2006) Nomograms for prostate can-
cer. BJU Int 98(1):39–46 Review
67. Roobol MJ, Zappa M, Määttänen L, Ciatto S (2007) The value of
diVerent screening tests in predicting prostate biopsy outcome in
screening for prostate cancer data from a multicenter study (ERS-
PC). Prostate 67(4):439–446
68. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino
E, Brand T, Troyer DA, Leach RJ, Thompson IM (2006) External
validation of the Prostate Cancer Prevention Trial risk calculator
in a screened population. Urology 68(6):1152–1155123
